This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
ARIAD Pharmaceuticals, Inc.
Drug Names(s): Ridaforolimus, AP23573, ARIAD573, MK-8669, deforolimus, Jenzyl (EU)
Description: AP23573 is a small molecule inhibitor of the critical cell-signaling protein, mTOR, which regulates the response of tumor cells to nutrients and growth factors, and controls tumor blood supply and angiogenesis through effects on Vascular Endothelial Growth Factor (VEGF) in tumor and endothelial cells. AP23573 also blocks the proliferation and migration of vascular smooth muscle cells, the primary cause of narrowing and reblockage of injured arteries, and is an analog of sirolimus, another mTOR inhibitor that has been approved for use in drug-eluting stents.
Deal Structure: In July 2007, ARIAD Pharmaceuticals and Merck & Co. announced that they entered into a global collaboration to jointly develop and commercialize ridaforolimus (formerly known as deforolimus) for use in cancer.
Both ARIAD and Merck share overall responsibility for global development and commercialization of ridaforolimus. In the United States, ARIAD will distribute and sell ridaforolimus for all cancer indications and book all sales, and ARIAD and Merck will co-promote ridaforolimus. ARIAD and Merck will each receive 50 percent of the income from such sales. Outside the United States, Merck will distribute, sell and promote ridaforolimus and book all sales. Merck will pay ARIAD tiered double-digit royalties on such end-market sales of ridaforolimus.
In the United States, ARIAD will have primary responsibility for development of ridaforolimus in the metastatic sarcoma indication. Merck and ARIAD will have joint responsibility in the United States for development of all other...See full deal structure in Biomedtracker
Pink Sheet ‘Complete Response’ Letters
Additional information available to subscribers only: